Clinical Trial Update: Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating hydroxychloroquine to increase PAR-4 tumor suppressor levels in oligometastatic/prostate cancer; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Patrick Hensley | Conditions: Prostate Cancer Recurrent | Phase 2 | Status: COMPLETED | Results posted: 2025-04-11